Insider · CIK 0001363984
Ryan D Maynard
Files at IOVA (IOVANCE BIOTHERAPEUTICS, INC.), FHTX (Foghorn Therapeutics Inc.). First filing Nov 14, 2024, latest Nov 14, 2024.
Ryan D Maynard files SEC Form 4 as director and CFO at IOVA (IOVANCE BIOTHERAPEUTICS, INC.), and also at FHTX (Foghorn Therapeutics Inc.). Since Nov 14, 2024, Ryan D Maynard has reported 0 open-market buys worth $0 and 1 open-market sell worth $503k, the latest filed on Nov 14, 2024.
A track record needs three past buys with six months of prices behind them; Ryan D Maynard has 0, so none is measured yet.
The newest scored trade: sold $503k of IOVA on Nov 12, 2024, filed Nov 14, 2024, scored 38 (weak).
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
IOVA: IOVANCE BIOTHERAPEUTICS, INC.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 38Weak | IOVAsell IOVANCE BIOTHERAPEUTICS, INC. | $503k 50,000 shares | -87% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Nov 12, 2024 | IOVA IOVANCE BIOTHERAPEUTICS, INC. | 50,000 0.02% of outstanding | $503k | Nov 12, 2024 | none |
Transactions
Every row this insider has filed, 5 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 23, 2026 | FHTX Foghorn Therapeutics Inc. | AGrant or award Stock Option (right to buy)derivative | +400,000 | $5.75 | $2.3M | 400,000 | Feb 24, 2026 |
| Jun 13, 2025 | IOVA IOVANCE BIOTHERAPEUTICS, INC. | AGrant or award Deferred Restricted Stock Unitderivative | +67,546 | $0.00 | $0 | 67,546 | Jun 17, 2025 |
| Nov 12, 2024 | IOVA IOVANCE BIOTHERAPEUTICS, INC. | MOption exercise Common Stock | +50,000 | $7.45 | $373k | 57,500 | Nov 14, 2024 |
| Nov 12, 2024 | IOVA IOVANCE BIOTHERAPEUTICS, INC. | SOpen-market sale Common Stock | -50,000 | $10.06 | $503k | 7,500 | Nov 14, 2024 |
| Nov 12, 2024 | IOVA IOVANCE BIOTHERAPEUTICS, INC. | MOption exercise Stock Option (right to buy)derivative | -50,000 | $0.00 | $0 | 0 | Nov 14, 2024 |
Questions about Ryan D Maynard
Answered from the filings on this page, as of the latest one.
Is Ryan D Maynard buying or selling?
Not in the last 12 months. Ryan D Maynard's latest open-market trade on SEC Form 4 was sold $503k of IOVA on Nov 12, 2024.
How did Ryan D Maynard's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Ryan D Maynard has 0.
Where does Ryan D Maynard file Form 4?
Ryan D Maynard has filed Form 4 at IOVA (IOVANCE BIOTHERAPEUTICS, INC.); FHTX (Foghorn Therapeutics Inc.) as Chief Financial Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.